伴发基因突变对携带RUNX1::RUNX1T1融合基因急性髓系白血病患者预后影响的研究进展

doi:10.3969/j.issn.1673-8640.2025.02.015

摘要/Abstract

摘要：

携带RUNX1::RUNX1T1融合基因的急性髓系白血病（AML）是一类临床常见且具有独特临床特征的白血病。尽管初始化疗可以获得良好的缓解率，但近年来的研究发现此类患者预后存在显著异质性。特别是当携带RUNX1::RUNX1T1的AML患者伴有其他基因突变时，不同突变通过不同机制影响疾病的发生和预后。大多数基因突变会使携带RUNX1::RUNX1T1的AML患者的复发率明显升高，远期生存率下降，严重影响患者预后。文章对不同基因突变通过不同机制影响携带RUNX1::RUNX1T1的AML患者的发病和预后最新研究进展进行综述。

关键词: RUNX1::RUNX1T1融合基因, 基因突变, 急性髓系白血病, 预后

Abstract:

Acute myeloid leukemia（AML） with RUNX1::RUNX1T1 fusion is a common type of leukemia with unique clinical characteristics. Despite the good remission rates initially achieved with induction therapy，the recent studies have revealed significant heterogeneity in the prognosis of these patients. Particularly when AML with RUNX1::RUNX1T1 fusion is accompanied by other gene mutations，different mutations can influence the development and prognosis of the disease through various mechanisms. The presence of most gene mutations increases the relapse rate and decreases the long-term survival of these patient，which severely impacts their prognosis. This review summarizes the latest research progress on how different gene mutations affect the pathogenesis and prognosis of AML with RUNX1::RUNX1T1 fusion through various mechanisms.

Key words: RUNX1::RUNX1T1 fusion, Gene mutation, Acute myeloid leukemia, Prognosis

中图分类号:

R446.7

唐杰梅, 王彬彬, 刘娜, 唐古生. 伴发基因突变对携带RUNX1::RUNX1T1融合基因急性髓系白血病患者预后影响的研究进展[J]. 检验医学, 2025, 40(2): 186-191.

TANG Jiemei, WANG Binbin, LIU Na, TANG Gusheng. Influence of concomitant gene mutation on acute myeloid leukemia patients with RUNX1::RUNX1T1 fusion[J]. Laboratory Medicine, 2025, 40(2): 186-191.

参考文献 37

[1]	DÖHNER H, WEI A H, APPELBAUM F R, et al. Diagnosis and management of AML in adults:2022 recommendations from an international expert panel on behalf of the ELN[J]. Blood, 2022, 140(12):1345-1377.
[2]	DÖHNER H, ESTEY E, GRIMWADE D, et al. Diagnosis and management of AML in adults:2017 ELN recommendations from an international expert panel[J]. Blood, 2017, 129(4):424-447.
[3]	POLLYEA D A, ALTMAN J K, ASSI R, et al. Acute myeloid leukemia,version 3.2023,NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2023, 21(5):503-513.
[4]	CHRISTEN F, HOYER K, YOSHIDA K, et al. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21):an international study on 331 patients[J]. Blood, 2019, 133(10):1140-1151.
[5]	REJESKI K, DUQUE-AFONSO J, LÜBBERT M. AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms[J]. Oncogene, 2021, 40(38):5665-5676. DOI PMID
[6]	DUPLOYEZ N, MARCEAU-RENAUT A, BOISSEL N, et al. Comprehensive mutational profiling of core binding factor acute myeloid leukemia[J]. Blood, 2016, 127(20):2451-2459. DOI PMID
[7]	LAM K, ZHANG D E. RUNX1 and RUNX1-ETO:roles in hematopoiesis and leukemogenesis[J]. Front Biosci(Landmark Ed), 2012, 17(3):1120-1139.
[8]	WANG C, TU Z, CAI X, et al. A critical role of RUNX1 in governing megakaryocyte-primed hematopoietic stem cell differentiation[J]. Blood Adv, 2023, 7(11):2590-2605.
[9]	LIU N, SONG J, XIE Y, et al. Different roles of E proteins in t(8;21)leukemia:E2-2 compromises the function of AETFC and negatively regulates leukemogenesis[J]. Proc Natl Acad Sci U S A, 2019, 116(3):890-899.
[10]	LIU X, LIU Y, RAO Q, et al. Targeting fatty acid metabolism abrogates the differentiation blockade in preleukemic cells[J]. Cancer Res, 2024, 84(24):4233-4245.
[11]	VEGI N M, KLAPPACHER J, OSWALD F, et al. MEIS2 is an oncogenic partner in AML1-ETO-positive AML[J]. Cell Rep, 2016, 16(2):498-507. DOI PMID
[12]	AL-HARBI S, ALJURF M, MOHTY M, et al. An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1[J]. Blood Adv, 2020, 4(1):229-238.
[13]	ZHANG J, HUANG J, XU K, et al. DHX15 is involved in SUGP1-mediated RNA missplicing by mutant SF3B1 in cancer[J]. Proc Natl Acad Sci U S A, 2022, 119(49):e2216712119.
[14]	HARTMANN L, DUTTA S, OPATZ S, et al. ZBTB7A mutations in acute myeloid leukaemia with t(8;21)translocation[J]. Nat Commun, 2016,7:11733.
[15]	SCHMIDT F, KUNZE M, LOOCK A C, et al. Screening analysis of ubiquitin ligases reveals G2E3 as a potential target for chemosensitizing cancer cells[J]. Oncotarget, 2015, 6(2):617-632. DOI PMID
[16]	GOYAMA S, SCHIBLER J, GASILINA A, et al. UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO[J]. Leukemia, 2016, 30(3):728-739. DOI PMID
[17]	GRUSZKA A M, VALLI D, ALCALAY M. Wnt signalling in acute myeloid leukaemia[J]. Cells, 2019, 8(11):1403.
[18]	SCHESSL C, RAWAT V P, CUSAN M, et al. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice[J]. J Clin Invest, 2005, 115(8):2159-2168.
[19]	ISHIKAWA Y, KAWASHIMA N, ATSUTA Y, et al. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11[J]. Blood Adv, 2020, 4(1):66-75.
[20]	YU G, YIN C, JIANG L, et al. Amyloid precursor protein cooperates with c-KIT mutation/overexpression to regulate cell apoptosis in AML1-ETO-positive leukemia via the PI3K/AKT signaling pathway[J]. Oncol Rep, 2016, 36(3):1626-1632.
[21]	SHIMA T, MIYAMOTO T, KIKUSHIGE Y, et al. The ordered acquisition of class Ⅱ and class Ⅰ mutations directs formation of human t(8;21)acute myelogenous leukemia stem cell[J]. Exp Hematol, 2014, 42(11):955-965.
[22]	WICHMANN C, QUAGLIANO-LO COCO I, YILDIZ Ö, et al. Activating c-KIT mutations confer oncogenic cooperativity and rescue RUNX1/ETO-induced DNA damage and apoptosis in human primary CD34+ hematopoietic progenitors[J]. Leukemia, 2015, 29(2):279-289.
[23]	XU W, YANG H, LIU Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases[J]. Cancer Cell, 2011, 19(1):17-30. DOI PMID
[24]	赵霄晨, 杨柯, 赵强, 等. 伴JAK2 V617F变异的AML-ETO阳性急性髓系白血病一例[J]. 中华医学遗传学杂志, 2022, 39(12):1433-1434.
[25]	HAFERLACH T, MEGGENDORFER M. More than a fusion gene:the RUNX1-RUNX1T1 AML[J]. Blood, 2019, 133(10):1006-1007.
[26]	OPATZ S, BAMOPOULOS S A, METZELER K H, et al. The clinical mutatome of core binding factor leukemia[J]. Leukemia, 2020, 34(6):1553-1562. DOI PMID
[27]	XUAN L, WANG Y, YANG K, et al. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia:long-term follow-up of an open-label,multicentre,randomised,phase 3 trial[J]. Lancet Haematol, 2023, 10(8):e600-e611.
[28]	ERBA H P, MONTESINOS P, KIM H J, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia(QuANTUM-First):a randomised,double-blind,placebo-controlled,phase 3 trial[J]. Lancet, 2023, 401(10388):1571-1583.
[29]	POLLYEA D A, BIXBY D, PERL A, et al. NCCN guidelines insights:acute myeloid leukemia,version 2.2021[J]. J Natl Compr Canc Netw, 2021, 19(1):16-27.
[30]	CHO B S, MIN G J, PARK S S, et al. Prognostic impacts of D816V KIT mutation and peri-transplant RUNX1-RUNX1T1 MRD monitoring on acute myeloid leukemia with RUNX1-RUNX1T1[J]. Cancers(Basel), 2021, 13(2):336.
[31]	KONG J, ZHENG F M, WANG Z D, et al. Avapritinib is effective for treatment of minimal residual disease in acute myeloid leukemia with t(8;21)and kit mutation failing to immunotherapy after allogeneic hematopoietic stem cell transplantation[J]. Bone Marrow Transplant, 2023, 58(7):777-783.
[32]	WANG Q, HU Y, GAO L, et al. Pediatric acute myeloid leukemia with t(8;21)and KIT mutation treatment with avapritinib post-stem cell transplantation:a report of four cases[J]. Ann Hematol, 2024, 103(9):3795-3800.
[33]	CHI S G, MINAMI Y. Emerging targeted therapy for specific genomic abnormalities in acute myeloid leukemia[J]. Int J Mol Sci, 2022, 23(4):2362.
[34]	QIN W, CHEN X, SHEN H J, et al. Comprehensive mutation profile in acute myeloid leukemia patients with RUNX1-RUNX1T1 or CBFB-MYH11 fusions[J]. Turk J Haematol, 2022, 39(2):84-93.
[35]	DINARDO C D, SCHUH A C, STEIN E M, et al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed,mutant-IDH2 acute myeloid leukaemia(AG221-AML-005):a single-arm,phase 1b and randomised,phase 2 trial[J]. Lancet Oncol, 2021, 22(11):1597-1608.
[36]	FRUCHTMAN H, AVIGAN Z M, WAKSAL J A, et al. Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia[J]. Leukemia, 2024, 38(5):927-935. DOI PMID
[37]	SHAH B, MATTISON R J, ABBOUD R, et al. Acute lymphoblastic leukemia,version 2. 2024,NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2024, 22(8):563-576.